Indian Medtechs Call US Tariffs A Challenge To Growth And Seek Reciprocal Regulatory Access

Indian Medtech Firms Want Level Playing Field On Tariffs And Action On US Non-Tariffs Barriers

 
• By Shubham Singh
  
Indian medtech industry leaders now argue that the potential benefits may be limited if systemic trade imbalances and regulatory hurdles are not addressed.

More from Asia

More from Medtech Insight